WO2002066014A3 - Cubic liquid crystalline compositions and methods for their preparation - Google Patents

Cubic liquid crystalline compositions and methods for their preparation Download PDF

Info

Publication number
WO2002066014A3
WO2002066014A3 PCT/US2002/004776 US0204776W WO02066014A3 WO 2002066014 A3 WO2002066014 A3 WO 2002066014A3 US 0204776 W US0204776 W US 0204776W WO 02066014 A3 WO02066014 A3 WO 02066014A3
Authority
WO
WIPO (PCT)
Prior art keywords
liquid crystalline
cubic liquid
preparation
methods
mass fraction
Prior art date
Application number
PCT/US2002/004776
Other languages
French (fr)
Other versions
WO2002066014A2 (en
Inventor
Patrick Thomas Spicer
William Broderick Ii Small
Matthew Lawrence Lynch
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to CA002434647A priority Critical patent/CA2434647A1/en
Priority to MXPA03007440A priority patent/MXPA03007440A/en
Priority to EP02721031A priority patent/EP1361865A2/en
Priority to AU2002251986A priority patent/AU2002251986B2/en
Priority to JP2002565574A priority patent/JP2004521125A/en
Publication of WO2002066014A2 publication Critical patent/WO2002066014A2/en
Publication of WO2002066014A3 publication Critical patent/WO2002066014A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

A dry powder cubic gel precursor comprising an encapsulating compound, an amphiphile capable of forming a cubic liquid crystalline phase, and optionally a solvent. The encapsulating compound (A), amphiphile (B), and optional solvent (C) are present in mass fractions relative to each other such that 1.0 = a + b + c wherein a is the mass fraction of A, b is the mass fraction of B, and c is the mass fraction of C. Further, 1.0 > a > 0, 1.0 > b > 0, 1.0 > c > 0 and a, b, and c do not fall within a cubic liquid crystalline phase region on a phase diagram representing phase behavior of A, B, and C.
PCT/US2002/004776 2001-02-20 2002-02-19 Cubic liquid crystalline compositions and methods for their preparation WO2002066014A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002434647A CA2434647A1 (en) 2001-02-20 2002-02-19 Cubic liquid crystalline compositions and methods for their preparation
MXPA03007440A MXPA03007440A (en) 2001-02-20 2002-02-19 Cubic liquid crystalline compositions and methods for their preparation.
EP02721031A EP1361865A2 (en) 2001-02-20 2002-02-19 Cubic liquid crystalline compositions and methods for their preparation
AU2002251986A AU2002251986B2 (en) 2001-02-20 2002-02-19 Cubic liquid crystalline compositions and methods for their preparation
JP2002565574A JP2004521125A (en) 2001-02-20 2002-02-19 Cubic liquid crystal composition and method for preparing the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26995301P 2001-02-20 2001-02-20
US60/269,953 2001-02-20
US09/990,552 2001-11-21
US09/990,552 US7008646B2 (en) 2001-02-20 2001-11-21 Cubic liquid crystalline compositions and methods for their preparation

Publications (2)

Publication Number Publication Date
WO2002066014A2 WO2002066014A2 (en) 2002-08-29
WO2002066014A3 true WO2002066014A3 (en) 2003-09-04

Family

ID=26953991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/004776 WO2002066014A2 (en) 2001-02-20 2002-02-19 Cubic liquid crystalline compositions and methods for their preparation

Country Status (8)

Country Link
US (1) US7008646B2 (en)
EP (1) EP1361865A2 (en)
JP (1) JP2004521125A (en)
CN (1) CN1638735A (en)
AU (1) AU2002251986B2 (en)
CA (1) CA2434647A1 (en)
MX (1) MXPA03007440A (en)
WO (1) WO2002066014A2 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
GB0318448D0 (en) * 2003-08-06 2003-09-10 Syngenta Ltd Formulation
JP2007504256A (en) * 2003-09-01 2007-03-01 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド Compositions and methods for delivery of bioactive agents
WO2005063370A1 (en) * 2003-12-31 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable ill-defined cubic nanosized particles in a ternary aqueous phase
JP4966018B2 (en) 2004-01-23 2012-07-04 カムルス エービー Ternary non-lamellar lipid composition
JP4266982B2 (en) * 2004-07-19 2009-05-27 ザ プロクター アンド ギャンブル カンパニー Method for forming a gel containing ingredients therein
KR100853958B1 (en) * 2004-07-19 2008-08-25 더 프록터 앤드 갬블 캄파니 Process for forming a gel containing an ingredient therein
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
EP2206495B1 (en) 2005-01-14 2012-11-21 Camurus AB Topical bioadhesive formulations
ATE501710T1 (en) 2005-01-14 2011-04-15 Camurus Ab SOMATOSTATIN ANALOG FORMULATIONS
JP5127466B2 (en) 2005-01-21 2013-01-23 カムルス エービー Pharmaceutical lipid composition
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
CN101217940B (en) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1 analogue formulations
CN100430372C (en) * 2006-05-18 2008-11-05 复旦大学 Double ingredients organic gelatin and liquid crystal gelatin and its preparation method
WO2007140510A1 (en) * 2006-06-02 2007-12-13 Monash University Agrochemical composition comprising liquid crystal particles
DE102007025898A1 (en) * 2007-06-01 2008-12-04 Matthias W. Dr. Amrein Treatment of surfactants
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
US20100272859A1 (en) * 2007-08-28 2010-10-28 Pepsico, Inc. Delivery and controlled release of encapsulated water-insoluble flavorants
US9186640B2 (en) 2007-08-28 2015-11-17 Pepsico, Inc. Delivery and controlled release of encapsulated lipophilic nutrients
ATE513027T1 (en) 2008-04-02 2011-07-15 Nestec Sa FUNCTIONAL MESOPHASES BASED ON OLEYLETHANOLAMIDE
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
JP2014508166A (en) 2011-03-17 2014-04-03 トランスダーマル バイオテクノロジ インコーポレーテッド Local nitric oxide system and method of use thereof
SG11201407678YA (en) 2012-05-25 2014-12-30 Camurus Ab Somatostatin receptor agonist formulations
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9107853B2 (en) * 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
CA2947308A1 (en) 2013-05-09 2014-11-13 Zeenar Enterprises Pty Ltd Niacin formulation
CA2921073A1 (en) 2013-09-09 2015-03-12 The Procter & Gamble Company Process of making a liquid cleaning composition
US9730867B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Methods of forming a slurry with microcapsules formed from phosphate esters
US10154947B2 (en) 2016-01-06 2018-12-18 The Procter & Gamble Company Antiperspirant composition
US9732303B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Microcapsules formed from phosphate esters and compositions containing same
CN106389336B (en) * 2016-10-11 2019-06-18 中山大学 Liquid crystal nanoparticle precursor particles, self assembly liquid crystal nanoparticle and preparation method thereof
CN106491519B (en) * 2016-12-09 2020-01-21 广州中大南沙科技创新产业园有限公司 Cubic liquid crystal in-situ gel injection for local anesthetic and preparation method thereof
JP2019099478A (en) * 2017-11-30 2019-06-24 株式会社ファルネックス Powder particulate formulation having non-lamellar liquid crystal reconstruction capability
US10624830B2 (en) * 2017-11-30 2020-04-21 L'oreal Aqueous compositions with mangiferin for cosmetic applications
CN108478550B (en) * 2018-03-21 2021-06-25 山东师范大学 Medicine carrier based on alkyl glycoside lyotropic liquid crystal and preparation method and application thereof
CN108498849B (en) * 2018-05-08 2021-04-30 武汉百纳礼康生物制药有限公司 Liquid crystal gel hepatic artery embolism agent and preparation method thereof
CN108420787B (en) * 2018-05-15 2021-05-11 华中科技大学鄂州工业技术研究院 Cell factor type wound repair drug lyotropic liquid crystal gel nano preparation and preparation method thereof
CN109106686A (en) * 2018-08-07 2019-01-01 中山大学 Lysotropic liquid crystal injection and preparation method thereof for soft tissue regeneration vascularization promoting
CN109316440B (en) * 2018-09-29 2020-12-29 华中科技大学 Temperature-sensitive liquid crystal nano hydrogel and preparation method and application thereof
KR102096391B1 (en) * 2019-10-11 2020-04-06 (주)아이엠디팜 Omega-3-fatty acid composition forming liquid crystal structures
CN113336710A (en) * 2021-07-08 2021-09-03 山东理工大学 Minoxidil-3-methoxybenzoate crystal form for treating alopecia and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429224A1 (en) * 1989-11-17 1991-05-29 The Procter & Gamble Company Use of monoolein in the treatment of the periodontal pocket
WO2000023517A1 (en) * 1998-10-20 2000-04-27 Opta Food Ingredients, Inc. High-amylose starch-emulsifier composition and methods of making
WO2001068139A1 (en) * 2000-03-13 2001-09-20 Korea Institute Of Science And Technology Formulation solubilizing water-insoluble agents and preparation method thereof
WO2002002716A2 (en) * 2000-06-29 2002-01-10 The Procter & Gamble Company Cubic liquid crystalline compositions and methods for their preparation
WO2002064166A1 (en) * 2001-02-13 2002-08-22 Korea Institute Of Science And Technology Formulation to enhance bioavailability of bioactive matrials and preparation method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2740360B1 (en) 1995-10-25 1997-12-26 Rhone Poulenc Chimie WATER REDISPERSABLE GRANULES COMPRISING AN ACTIVE MATERIAL IN LIQUID FORM
BR9206593A (en) 1991-10-04 1995-11-28 Gs Biochem Ab Particles especially colloidal particles process of preparing them from a homogeneous liquid crystalline phase or L3 phase pharmaceutical composition and use of these particles
US5523111A (en) 1994-07-25 1996-06-04 Nickel; Gary B. Process for production of clathrate inclusion complexes
FR2726762B1 (en) * 1994-11-10 1997-01-17 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION IN THE FORM OF A DISPERSION OF AN OILY PHASE IN AN AQUEOUS PHASE STABILIZED WITH CUBIC GEL PARTICLES AND ITS PROCESS FOR OBTAINING IT
WO1996034628A1 (en) 1995-05-02 1996-11-07 Taisho Pharmaceutical Co., Ltd. Composition for oral administration
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US6017388A (en) * 1996-01-16 2000-01-25 Opta Food Ingredients, Inc. Starch-emulsifier composition and methods of making
NZ335676A (en) 1997-09-09 2001-03-30 Select Release L Coated particles comprising an exterior coating and a matrix comprising a liquid phase or liquid crystalline phase which is nanostructured
EP0948902A1 (en) 1998-03-13 1999-10-13 Societe Des Produits Nestle S.A. Food composition comprising a mesomorphic phase of monoglyceride
US6656385B2 (en) * 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6936187B2 (en) * 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429224A1 (en) * 1989-11-17 1991-05-29 The Procter & Gamble Company Use of monoolein in the treatment of the periodontal pocket
WO2000023517A1 (en) * 1998-10-20 2000-04-27 Opta Food Ingredients, Inc. High-amylose starch-emulsifier composition and methods of making
WO2001068139A1 (en) * 2000-03-13 2001-09-20 Korea Institute Of Science And Technology Formulation solubilizing water-insoluble agents and preparation method thereof
WO2002002716A2 (en) * 2000-06-29 2002-01-10 The Procter & Gamble Company Cubic liquid crystalline compositions and methods for their preparation
WO2002064166A1 (en) * 2001-02-13 2002-08-22 Korea Institute Of Science And Technology Formulation to enhance bioavailability of bioactive matrials and preparation method thereof

Also Published As

Publication number Publication date
EP1361865A2 (en) 2003-11-19
JP2004521125A (en) 2004-07-15
CA2434647A1 (en) 2002-08-29
MXPA03007440A (en) 2003-12-04
WO2002066014A2 (en) 2002-08-29
AU2002251986B2 (en) 2006-12-21
CN1638735A (en) 2005-07-13
US20020160040A1 (en) 2002-10-31
US7008646B2 (en) 2006-03-07

Similar Documents

Publication Publication Date Title
WO2002066014A3 (en) Cubic liquid crystalline compositions and methods for their preparation
WO2003060596A3 (en) Semiconductor liquid crystal composition and methods for making the same
CA2411918A1 (en) Cubic liquid crystalline compositions and methods for their preparation
CA2434655A1 (en) Cubic liquid crystalline phase precursor
HUP0400927A3 (en) New crystalline form and pure modafinil, process of preparing them, and pharmaceutical compositions containing the new crystalline form
CA2475933A1 (en) Spherical powder components and solid cosmetic compositions comprising thereof
WO2003043574A3 (en) Pharmaceutical compositions in particulate form
HUP0402280A3 (en) Micronized film-forming powder, composition containing them, preparation and application thereof
CA2010919A1 (en) Cosmetic sticks
CA2416576A1 (en) Articles, systems, and methods for dispensing volatile materials into the environment
WO2004064762A3 (en) Novel cocrystallization
AU2003209259A1 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
AU2268301A (en) Novel urea compounds, compositions and methods of use and preparation
AU2001237526A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
NO995540D0 (en) Composition comprising finely divided crystalline particles of budesonide
CA2229650A1 (en) Multiphase active ingredient-containing formulations
AU3885301A (en) Anti-mycobacterium compositions and methods of preparing and using same
CA2390649A1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
AU2003268314A1 (en) Process for the preparation of a dry pesticidal composition containing a dicarbodylate component
WO2001005355A3 (en) Formulations for il-11
AU3877700A (en) High protein edible compositions and method of preparing the same
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
CA2287333A1 (en) Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
WO2003039790A3 (en) Tightly agglomerated non-oxide particles and method for producing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 02805147.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2434647

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002251986

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007440

Country of ref document: MX

Ref document number: 2002565574

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002721031

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002721031

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642